You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Novo Nordisk said it had repurchased 42,604,179 B shares since 4 February 2026 for DKK 11,808,013,711, part of a DKK 15 billion, 12-month program.
Novo Nordisk A/S disclosed that Executive Vice President, R&D and Chief Scientific Officer Martin Holst Lange sold 12,000 shares at DKK 285.00 on 20 26-11-04, totaling DKK 3,420 ,000 .0 0.
Novo reported adjusted sales growth of 4%, reaching 79.2 billion Danish kroner, and raised 2026 adjusted sales and operating profit guidance to minus 2% to plus 2% at CER. Free cash flow is now expected between 60 and 70 billion Danish kroner.
Novo Nordisk A/S raised 2026 adjusted sales and adjusted operating profit growth expectations to -2% to +2% at CER, after Q3 2026 adjusted operating profit increased 27% to DKK 31,720 million.
Novo Nordisk repurchased 41,714,179 B shares for DKK 11,564,364,801 as of 2 November 2026, averaging DKK 277.23 per share. Its overall program authorizes up to DKK 15 billion from 4 February 2026.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVO
this stock
Novo Nordisk A S
|
$183.52B | -18.2% | — | — | 0.9% |
|
LLY
ELI LILLY & Co
|
$1.36T | +34.3% | +44.7% | 46.9 | 0.8% |
|
JNJ
Johnson & Johnson
|
$687.89B | +38.1% | +6.0% | 43.4 | 0.7% |
|
ABBV
AbbVie Inc.
|
$521.50B | +29.1% | +8.6% | 50.8 | 0.9% |
|
MRK
Merck & Co., Inc.
|
$364.26B | +40.4% | +1.3% | 152.3 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVO | +3.3% | +7.2% | -5.8% | +4.1% | -18.2% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | +0.7% | +8.4% | -6.3% | +4.3% | -28.8% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
